海西新药(02637)：林慧怡获委任为联席公司秘书

Core Viewpoint - Hai Xi New Drug (02637) announced the resignation of Ms. Chen Xiaolin from multiple positions effective November 21, 2025, and the appointment of Ms. Lin Huiyi as the new co-secretary and authorized representative [1] Group 1 - Ms. Chen Xiaolin has resigned as co-secretary of the company [1] - Ms. Chen Xiaolin has also resigned as the authorized representative under the Hong Kong Listing Rules and Companies Ordinance [1] - Ms. Lin Huiyi has been appointed as the new co-secretary and authorized representative effective November 21, 2025 [1]